Format

Send to

Choose Destination
Neuropeptides. 2009 Jun;43(3):187-92. doi: 10.1016/j.npep.2009.04.004. Epub 2009 May 20.

A novel GalR2-specific peptide agonist.

Author information

1
Department of Neurochemistry, Stockholm University, Svante Arrheniusv. 21A, SE-10691 Stockholm, Sweden. johanr@neurochem.su.se

Abstract

The galanin peptide family and its three receptors have with compelling evidence been implicated in several high-order physiological disorders. The co-localization with other neuromodulators and the distinct up-regulation during and after pathological disturbances has drawn attention to this neuropeptide family. In the current study we present data on receptor binding and functional response for a novel galanin receptor type 2 (GalR2) selective chimeric peptide, M1145 [(RG)(2)-N-galanin(2-13)-VL-(P)(3)-(AL)(2)-A-amide]. The M1145 peptide shows more than 90-fold higher affinity for GalR2 over GalR1 and a 76-fold higher affinity over GalR3. Furthermore, the peptide yields an agonistic effect in vitro, seen as an increase in inositol phosphate (IP) accumulation, both in the absence or the presence of galanin. The peptide design with a N-terminal extension of galanin(2-13), prevails new insights in the assembly of novel subtype specific ligands for the galanin receptor family and opens new possibilities to apply the galanin system as a putative drug target.

PMID:
19467704
DOI:
10.1016/j.npep.2009.04.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center